Immunohistochemistry or IHC
Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
Diagnostics 2023 January [Link] Lina Zuccatosta, Tommaso Bizzarro, Giulio Rossi, Graziana Gallo, Stefano Gasparini, Andrea Ambrosini-Spaltro Abstract (1) Background. In the differential diagnosis between sarcomatoid carcinoma (SC) and sarcomatoid mesothelioma (SM), we aimed to investigate the role of Claudin-4 and BAP1, a panel recently used to distinguish conventional carcinoma from epithelioid mesothelioma. (2) Methods. We…
Read MoreCarbon-ion beam irradiation in combination with cisplatin effectively suppresses xenografted malignant pleural mesothelioma
American Journal of Cancer Research 2022 December 15 [Link] Sei Sai, Taiju Yamada, Keiko Ito, Nobuyuki Kanematsu, Masao Suzuki, Mitsuhiro Hayashi, Masashi Koto Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer. This study investigated the growth-inhibitory effects of the combination of carbon ion beam irradiation (IR) and cisplatin (CDDP) on MPM xenografts. Carbon-ion…
Read MoreAXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
Journal of Personalized Medicine 2022 December 2 [Link] Federica Zito Marino, Carminia Maria Della Corte, Vincenza Ciaramella, Stefania Erra, Andrea Ronchi, Alfonso Fiorelli, Giovanni Vicidomini, Mario Santini, Giosuè Scognamiglio, Floriana Morgillo, Fortunato Ciardiello, Renato Franco, Marina Accardo Abstract Malignant pleural mesothelioma (MPM) is a highly lethal malignancy that unfortunately cannot benefit from molecularly targeted therapies.…
Read MoreNR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreUsefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study
Lung Cancer 2022 November 19 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Takahiko Kasai, Kei Kushitani, Yukio Takeshima, Kenzo Hiroshima, Akinori Iwasaki, Kazuki Nabeshima Abstract Objectives: BAP1, CDKN2A, and NF2 are the most frequently altered genes in pleural mesotheliomas (PM). Discriminating PM from benign mesothelial proliferation (BMP)…
Read MoreHistopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates
Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…
Read MoreRhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
Scientific Reports 2022 November 2 [Link] Takuya Hiratsuka, Takushi Yamamoto, Akihiko Yoshizawa, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract Diagnostic markers of malignant mesothelioma (MM) have been extensively investigated. Immunohistochemistry (IHC) markers, such as calretinin, have been used for pathologic diagnosis. However, more diagnostic markers are required to improve the specificity and sensitivity of pathologic diagnosis. This…
Read MoreLoss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases
World Journal of Surgical Oncology 2022 October 24 [Link] He-Liang Wu, Zhi-Ran Yang, Yan-Dong Su, Ru Ma, Xue-Mei Du, Ying Gao, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore…
Read MoreCytological Diagnosis of Malignant Mesothelioma: A Case Series
Journal of Cytology 2022 July-September [Link] Sakshi Dahiya, Meeta Singh, Shyama Jain, Bembem Khuraijam, Naman Suroya, Shramana Mandal Abstract Background: Mesotheliomas are neoplasms of the serosal lining of the body cavities. Diagnosis requires a multimodal approach of clinical findings, cytology, and histopathology with immunohistochemistry (IHC). The published sensitivity of cytology for diagnosing mesothelioma ranges from…
Read MoreNew candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin
Tissue & Cell 2022 September 6 [Link] Ozlem Ucer, Nevin Kocaman Abstract Objectives: Malignant mesothelioma (MM) is a primary malignant tumour with a very bad prognosis, which develops from the mesothelial cells lining the serosal surfaces. Because MM can show a wide variety of histological patterns and its cytomorphological features are quite extensive, it is…
Read More